Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Top Cited Papers
- 20 October 2020
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 32 (1), 34-48
- https://doi.org/10.1016/j.annonc.2020.10.478
Abstract
No abstract availableKeywords
Funding Information
- University of Heidelberg
- SCOR Grant Leukemia and Lymphoma
- National Institute of Health (3P50CA126752)
- National Cancer Institute
This publication has 152 references indexed in Scilit:
- Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysisCritical Care, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndromeBlood, 2012
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cellsBlood, 2012
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6International Journal of Biological Sciences, 2012
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2011
- Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experienceCytotherapy, 2010
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoJCI Insight, 2007
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyThe New England Journal of Medicine, 2003